181 related articles for article (PubMed ID: 29691476)
1. Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.
AlQarni S; Al-Sheikh Y; Campbell D; Drotar M; Hannigan A; Boyle S; Herzyk P; Kossenkov A; Armfield K; Jamieson L; Bailo M; Lieberman PM; Tsimbouri P; Wilson JB
Oncogene; 2018 Jul; 37(29):3998-4012. PubMed ID: 29691476
[TBL] [Abstract][Full Text] [Related]
2. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
3. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
4. The interaction between Vav1 and EBNA1 promotes survival of Burkitt's lymphoma cells by down-regulating the expression of Bim.
Wang R; Wang J; Zhang N; Wan Y; Liu Y; Zhang L; Pan S; Zhang C; Zhang H; Cao Y
Biochem Biophys Res Commun; 2019 Apr; 511(4):787-793. PubMed ID: 30833082
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
6. Potential cellular functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus.
Westhoff Smith D; Sugden B
Viruses; 2013 Jan; 5(1):226-40. PubMed ID: 23325328
[TBL] [Abstract][Full Text] [Related]
7. An EBV recombinant deleted for residues 130-159 in EBNA3C can deregulate p53/Mdm2 and Cyclin D1/CDK6 which results in apoptosis and reduced cell proliferation.
Shukla SK; Jha HC; El-Naccache DW; Robertson ES
Oncotarget; 2016 Apr; 7(14):18116-34. PubMed ID: 26908453
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
9. EBNA1.
Frappier L
Curr Top Microbiol Immunol; 2015; 391():3-34. PubMed ID: 26428370
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies.
Sivachandran N; Sarkari F; Frappier L
PLoS Pathog; 2008 Oct; 4(10):e1000170. PubMed ID: 18833293
[TBL] [Abstract][Full Text] [Related]
11. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
14. Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival.
Frappier L
Viruses; 2012 Sep; 4(9):1537-1547. PubMed ID: 23170171
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Flavell JR; Baumforth KR; Wood VH; Davies GL; Wei W; Reynolds GM; Morgan S; Boyce A; Kelly GL; Young LS; Murray PG
Blood; 2008 Jan; 111(1):292-301. PubMed ID: 17720884
[TBL] [Abstract][Full Text] [Related]
17. Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.
Rühl J; Citterio C; Engelmann C; Haigh T; Dzionek A; Dreyer J; Khanna R; Taylor GS; Wilson JB; Leung CS; Münz C
J Clin Invest; 2019 May; 129(5):2071-2087. PubMed ID: 31042161
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation sites of Epstein-Barr virus EBNA1 regulate its function.
Duellman SJ; Thompson KL; Coon JJ; Burgess RR
J Gen Virol; 2009 Sep; 90(Pt 9):2251-9. PubMed ID: 19439552
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
